Weglim 3 Tablet contains Glimepiride 3mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. It is typically prescribed as an adjunct to diet and exercise to improve glycemic control in patients whose diabetes cannot be adequately managed by lifestyle modifications alone. Weglim 3 is effective in lowering both fasting and postprandial blood glucose concentrations. The medication should be administered once daily with breakfast or the first main meal to minimize the risk of hypoglycemia. Dose adjustment may be necessary based on patient response and tolerability. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances such as nausea or abdominal discomfort. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Weglim 3 should be used under medical supervision to ensure optimal efficacy and safety in the management of type 2 diabetes mellitus.